The use of a monoclonal antibody that reduced circulating IgG levels, led to a decrease in preexisting neutralizing antibodies (NAbs) to adeno-associated virus (AAV). The study, which showed that this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback